Hi everybody, i'm launching a new business and need to inform potential customers/interested companies. I have zero experience with newsletters and email marketing. Do i need to buy a database and send it by myself or there are online services out there ? Thank you in advance.
Hi everybody, i'm launching a new business and need to inform potential customers/interested companies. I have zero experience with newsletters and email marketing. Do i need to buy a database and send it by myself or there are online services out there ? Thank you in advance.
Buongiorno,
dispongo di un'area commerciale a Roma Nord , Settebagni, Tenuta Santa Colomba. 250 metri quadri tra uffici e magazzino oltre a 1000 mq di area esterna privata. Non essendo di Roma, cerco interessati.
Hi everyone,
about a year ago, I did some work for a foreign company that owned a small commercial property in northern Rome. The company paid me with the ownership of the property. It's approximately 1,500 square meters, of which about 250 are offices and a warehouse; the rest is open. It's fenced with an automatic gate. It's located in a commercial/industrial area. Very close to the GRA , just outside the city. I don't live in Rome and want to sell it. If anyone is interested, for a business or any other reason (investment) , I'm open to discussion. Thanks!
Could you please provide your opinion on the operations of two companies involved in the production of an excipient intended for marketing as a medical device? The period is between 2015 and 2018 in Europe.
Company A is the medical device manufacturer company with its own ISO13485 certification and CE.
Company B is the actual manufacturer and supplier of the main chemical molecule (the excipient).
The two companies signed the production contract and quality agreement in the third quarter of 2015.
Company B is not a GMP company and only holds ISO9001:2008 certification. Company B was audited at the end of 2014. 15 non-conformities were found, which were closed in December 2015. In the meantime, however, several batches were produced and delivered to Company A. The rules were supposed to be changed in March 2016 with the introduction of risk assessment (please confirm this). However, the two companies continued to operate until mid-2017 without evidence of having taken corrective actions. In late 2017, some supplies were contaminated and the supplies were interrupted. The two companies agreed to rework to resolve the problem and restart supplies. At the end of 2017, Company A issued a Quality Summary Report declaring Supplier B suitable for the production of the molecule, based on the 2014 audit and the 2015 QA, without making any mention of the defective supplies.
Question is if the process followed presents irregularities